Avalo Therapeutics (AVTX) Competitors $13.99 +0.32 (+2.34%) Closing price 04:00 PM EasternExtended Trading$14.00 +0.00 (+0.04%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTX vs. ERAS, GHRS, MGTX, SNDL, ESPR, KROS, SIGA, IVA, CMPS, and MNPRShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Erasca (ERAS), GH Research (GHRS), MeiraGTx (MGTX), SNDL (SNDL), Esperion Therapeutics (ESPR), Keros Therapeutics (KROS), Siga Technologies (SIGA), Inventiva (IVA), COMPASS Pathways (CMPS), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry. Avalo Therapeutics vs. Its Competitors Erasca GH Research MeiraGTx SNDL Esperion Therapeutics Keros Therapeutics Siga Technologies Inventiva COMPASS Pathways Monopar Therapeutics Avalo Therapeutics (NASDAQ:AVTX) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership. Is AVTX or ERAS more profitable? Erasca's return on equity of -31.19% beat Avalo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -48.48% -35.94% Erasca N/A -31.19%-26.34% Which has preferable earnings and valuation, AVTX or ERAS? Avalo Therapeutics has higher revenue and earnings than Erasca. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$440K418.11-$35.13MN/AN/AErascaN/AN/A-$161.65M-$0.45-5.36 Which has more risk & volatility, AVTX or ERAS? Avalo Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Erasca has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Does the media prefer AVTX or ERAS? In the previous week, Erasca had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 7 mentions for Erasca and 4 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.62 beat Erasca's score of 0.58 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Erasca 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of AVTX or ERAS? 87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 0.3% of Avalo Therapeutics shares are owned by insiders. Comparatively, 14.4% of Erasca shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend AVTX or ERAS? Avalo Therapeutics currently has a consensus price target of $31.67, suggesting a potential upside of 126.35%. Erasca has a consensus price target of $3.71, suggesting a potential upside of 54.12%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Avalo Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80Erasca 2 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.38 SummaryAvalo Therapeutics beats Erasca on 7 of the 12 factors compared between the two stocks. Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$183.97M$2.61B$6.02B$10.45BDividend YieldN/A57.78%5.73%4.82%P/E RatioN/A22.5685.1227.24Price / Sales418.11752.53589.92133.47Price / CashN/A26.3325.7730.18Price / Book1.095.3612.676.76Net Income-$35.13M$33.06M$3.32B$276.59M7 Day Performance3.78%0.71%0.50%0.86%1 Month Performance31.36%10.16%9.42%8.17%1 Year Performance50.59%-0.86%79.11%43.66% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics3.3585 of 5 stars$13.99+2.3%$31.67+126.4%+43.3%$183.97M$440K0.0040Positive NewsAnalyst ForecastERASErasca2.5526 of 5 stars$2.33-3.7%$3.71+59.4%-12.7%$686.48MN/A-5.18120GHRSGH Research2.7263 of 5 stars$13.06-0.3%$32.00+145.0%+88.6%$681.57MN/A-17.6510News CoverageAnalyst ForecastMGTXMeiraGTx4.1397 of 5 stars$8.41-0.5%$24.00+185.4%+84.2%$679.78M$37.92M-4.12300Gap DownSNDLSNDL3.3062 of 5 stars$2.56-0.8%$4.50+75.8%+24.6%$677.96M$671.81M-9.482,516Gap DownESPREsperion Therapeutics3.7476 of 5 stars$3.12-5.5%$7.00+124.4%+38.1%$665.35M$332.31M-6.37200KROSKeros Therapeutics2.3908 of 5 stars$15.62-2.0%$30.00+92.1%-73.4%$647.41M$3.55M50.39100News CoverageSIGASiga Technologies1.553 of 5 stars$8.23-8.0%N/A+20.2%$640.87M$138.72M7.2840IVAInventiva3.2366 of 5 stars$6.24-4.4%$15.57+149.5%+143.9%$624.67M$9.95M0.00100Analyst RevisionGap DownHigh Trading VolumeCMPSCOMPASS Pathways3.2279 of 5 stars$6.29-2.2%$16.29+158.9%+4.5%$616.90MN/A-3.42120News CoverageAnalyst ForecastMNPRMonopar Therapeutics2.253 of 5 stars$99.50+0.1%$97.33-2.2%+1,755.5%$613.23MN/A-29.8810Analyst Forecast Related Companies and Tools Related Companies Erasca Competitors GH Research Competitors MeiraGTx Competitors SNDL Competitors Esperion Therapeutics Competitors Keros Therapeutics Competitors Siga Technologies Competitors Inventiva Competitors COMPASS Pathways Competitors Monopar Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTX) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | Sponsored2 Nobel Prize winners warn of once-in-a-generation wealth shift…An unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and l...Porter & Company | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | SponsoredBuy this stock before Tesla’s November 6 announcementThe End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
